This medication belongs to the glucagon-like peptide-1 (GLP-1) receptor agonists, working by mimicking the effects of natural GLP-1 in the body
Additionally, liraglutide improved nociceptive thresholds and reversed histopathological damage of the sciatic nerve in diabetic rats induced by nicotinamide and streptozotocin [11]
What Clinicians Should Expect Next May 11, 2026 Articles, Diabetes, GLP- 1 Agonist Therapy Center, GLP-1 Agonist Therapy Center, Obesity, Obesity, Therapies, Type 2 Diabetes, Type 2 Diabetes 1,367 views The rapid rise of GLP-1 receptor agonists has transformed diabetes treatment and obesity management over the past decade
FDA labeling includes a boxed warning regarding thyroid C-cell tumors based on rodent studies, though human relevance remains uncertain
It is designed to be administered once weekly via a subcutaneous injection, and its primary purpose is the treatment of obesity and overweight